

Table 1. Member Impact for Proposed High Performance Generic Step Therapy and Proposed Targeted Brand Fourth Tier Copay, by Drug Class

Drug Class	Condition Treated	Number of Members That Would Be Impacted
Proton Pump Inhibitors	Acid Reflux	4,419
Statins (HMG-CoA Reductase Inhibitors)	High Cholesterol	2,939
Cox-2 Inhibitors/ Nonsteroidal Anti-Inflammatory Drugs	Pain	2,509
Serotonin-Norepinephrine Reuptake Inhibitors	Depression	2,341
Angiotensin-Converting-Enzyme Inhibitors / Angiotensin II Receptor Blockers	High Blood Pressure	896
Nasal Steroids	Allergy	740
Urinary Antispasmodics	Urinary Incontinence	555
Hypnotics	Insomnia	485
Triptans	Headache	474
Prostaglandin Analogs	Glaucoma	460
Alpha-Reductase Inhibitors	Enlarged Prostate	448
Anti-Acne Medications	Acne	419
Selective Serotonin Reuptake Inhibitors	Depression	386
Fibrates	High Cholesterol	106
Bisphosphonates	Osteoporosis	81